George Wingate Lloyd
Net Worth
Last updated:
What is George Wingate Lloyd net worth?
The estimated net worth of Mr. George Wingate Lloyd is at least $96,514,747 as of 6 Jun 2023. He owns shares worth $1,072,200 as insider, has earned $78,442,547 from insider trading and has received compensation worth at least $17,000,000 in Royalty Pharma plc.
What is the salary of George Wingate Lloyd?
Mr. George Wingate Lloyd salary is $3,400,000 per year as Executive Vice President of Investments & Gen. Counsel in Royalty Pharma plc.
How old is George Wingate Lloyd?
Mr. George Wingate Lloyd is 66 years old, born in 1959.
What stocks does George Wingate Lloyd currently own?
As insider, Mr. George Wingate Lloyd owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Royalty Pharma plc (RPRX) | Executive Vice President of Investments & Gen. Counsel | 30,000 | $35.74 | $1,072,200 |
What does Royalty Pharma plc do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
George Wingate Lloyd insider trading
Royalty Pharma plc
Mr. George Wingate Lloyd has made 51 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 79,099 units of RPRX stock worth $2,674,812 on 6 Jun 2023.
The largest trade he's ever made was exercising 165,852 units of RPRX stock on 16 Nov 2021. As of 6 Jun 2023 he still owns at least 30,000 units of RPRX stock.
Royalty Pharma key executives
Royalty Pharma plc executives and other stock owners filed with the SEC:
- Dr. James Folmar Reddoch Ph.D. (55) Executive Vice President, Chief Scientific Officer and Co-Head of Research & Investments
- Mr. Christopher Hite (57) Vice Chairman & Executive Vice President
- Mr. George Wingate Lloyd (66) Executive Vice President of Investments & Gen. Counsel
- Mr. Pablo Gerardo Legorreta (61) Founder, Chairman & Chief Executive Officer